A late-stage study of Mesoblast’s off-the-shelf stem cell therapy for acute graft-versus-host disease (GVHD) has hit its main goal, setting up an imminent U.S…
Merck's ERK drug had a low response rate but could be used in combinations for BRAF-mutant cancers.
The careful optimization of tumor-bearing humanized models leads to highly useful preclinical immuno-oncology platforms for accelerated immunotherapy…
Scientists at the University of Cambridge have shown in animal models that reprogramming patients’ own skin cells may be an effective way to treat MS.
Months after losing its hepatitis C collaboration with Janssen, Achillion is trying to cut costs.
In this week's EuroBiotech Report, GW’s proof-of-concept trial fails, Arix hooks up with Ipsen, Medigene trial gets green light and more.
In our EuroBiotech roundup this week, biotechs file to raise $300 million, Minoryx spins off platform and Galapagos, MorphoSys post clinical data.
Raxone is currently in a phase 3 study on DMD patients who are taking glucocorticoids.
While the trial linked GWP42006 to around a 40% drop in focal seizures, the placebo triggered a similarly sharp decline.
Takeda has added another early-stage research partnership as it reboots its R&D operations, this time teaming with two Seattle-based academic centers.
Kite will use the ZFN gene editing platform to create next-generation, off-the-shelf CAR-T therapies to cement its position in the cell therapy space.